Royal DSM announced that DSM Venturing, its venture investment arm, has made an equity investment in skin microbiome company S-Biomedic NV. This investment completes S-Biomedic’s latest Series A financing round.
S-Biomedic is a Belgium based Life Sciences company pioneering a new approach to cosmetic and therapeutic potential of the skin microbiome.
This investment underlines DSM’s interest in the skin microbiome, an area it has identified as having significant growth potential. DSM already holds a strong position in gut microbiome research and solutions with its Culturelle product range.
“With its long-established expertise in skin biology and in-depth knowledge in the field of epidermal science DSM is well placed to extend its research and innovation focus on the skin microbiome. We have already made encouraging discoveries about how skin actives in our existing product portfolio work on the skin and scalp microbiome. Through this investment, we hope to foster further innovation in the field,” commented Rishabh Pande, Vice President Marketing & Innovation Personal Care & Aroma at DSM.
DSM Venturing has invested in more than 50 emerging innovative companies since its inception in 2001 and its current portfolio covers various industries. “DSM welcomes open innovation, as our history of investing in start-ups and taking on the role of incubator shows,” said Rob Beudeker, Investment Director at DSM Venturing.
